{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02940977",
      "OrgStudyIdInfo": {
        "OrgStudyId": "XH-16-028"
      },
      "Organization": {
        "OrgFullName": "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique",
      "OfficialTitle": "Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 1, 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 30, 2019",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 30, 2019",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "October 18, 2016",
      "StudyFirstSubmitQCDate": "October 19, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 21, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 8, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 10, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Jun Qi",
        "ResponsiblePartyInvestigatorTitle": "Head of the Urology Department",
        "ResponsiblePartyInvestigatorAffiliation": "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Shanghai Shen Kang Hospital Development Center",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To elucidate the role of CTC detection in the evaluation of risk level in PCa patients, and establish a mathematic model for predicting the pathological status.\nTo explore the possible subtle change in CTC condition after radical prostatectomy.",
      "DetailedDescription": "Detect and evaluate the CTC status (a total of 3 times: 1 day before sugery, 3/12 months after surgery) for all of the PCa patients enrolled. Analyze the CTC result with PSA level, needle biopsy and radiological imaging information.\nAnalyze the difference in CTC amount/Epithelial-Mesenchymal ratio between patients in different D'Amico risk level(low/intermediate/high).\nEstablish a mathematic model based on the CTC results and pathological condition observed in operation (OC, organ confined; EPE, extraprostatic extension; SVI, seminal vesicle invasion; LNI, lymph node invasion), and compare this model with the latest version of Partin table.\nDetect and compare the CTC and PSA level 3/12 months after surgery. Evaluate the radiological condition in 12 months after blood draw."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Prostatic Neoplasms",
          "Prostatic Adenoma"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Circulating tumor cell",
          "Epithelial to mesenchymal transition",
          "Prostate specific antigen (PSA)",
          "Partin table"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Observational",
      "PatientRegistry": "No",
      "DesignInfo": {
        "DesignObservationalModelList": {
          "DesignObservationalModel": [
            "Case-Only"
          ]
        },
        "DesignTimePerspectiveList": {
          "DesignTimePerspective": [
            "Prospective"
          ]
        }
      },
      "BioSpec": {
        "BioSpecRetention": "Samples With DNA",
        "BioSpecDescription": "Fresh blood 5 ml *2"
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "120",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Prostate cancer patients",
            "ArmGroupDescription": "Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Blood draws"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "Blood draws",
            "InterventionDescription": "Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Prostate cancer patients"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Circulating tumor cell (CTC) total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique",
            "PrimaryOutcomeDescription": "This step should be completed within the day when the peripheral venous blood is drawn.",
            "PrimaryOutcomeTimeFrame": "1 day before operation"
          },
          {
            "PrimaryOutcomeMeasure": "Pathological findings (whether the patient has: 1.OC, organ confined; 2.EPE, extraprostatic extension; 3. SVI, seminal vesicle invasion; 4. LNI, lymph node invasion) during the radical prostectomy, confirmed by pathology section result",
            "PrimaryOutcomeDescription": "The pathology section evaluation will be done by two pathologists independently. A third pathology expert will join to make a final decision if opposite results are given by the two pathologists.",
            "PrimaryOutcomeTimeFrame": "On the day of operation"
          },
          {
            "PrimaryOutcomeMeasure": "CTC total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique",
            "PrimaryOutcomeDescription": "This step should be completed within the day when the peripheral venous blood is drawn.",
            "PrimaryOutcomeTimeFrame": "3 months after operation"
          },
          {
            "PrimaryOutcomeMeasure": "CTC total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique",
            "PrimaryOutcomeDescription": "This step should be completed within the day when the peripheral venous blood is drawn.",
            "PrimaryOutcomeTimeFrame": "12 months after operation"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Prostate specific antigen (PSA) level measurement using peripheral venous blood",
            "SecondaryOutcomeDescription": "The blood should be drawn together with that for CTC detection",
            "SecondaryOutcomeTimeFrame": "3 months after operation"
          },
          {
            "SecondaryOutcomeMeasure": "Prostate specific antigen (PSA) level measurement using peripheral venous blood",
            "SecondaryOutcomeDescription": "The blood should be drawn together with that for CTC detection",
            "SecondaryOutcomeTimeFrame": "6 months after operation"
          },
          {
            "SecondaryOutcomeMeasure": "PSA level measurement using peripheral venous blood",
            "SecondaryOutcomeDescription": "The blood should be drawn together with that for CTC detection",
            "SecondaryOutcomeTimeFrame": "9 months after operation"
          },
          {
            "SecondaryOutcomeMeasure": "Radiological evaluation including isotope bone scanning and pelvic magnetic resonance imaging (MRI) scan",
            "SecondaryOutcomeDescription": "Radiological evaluation should be conducted after the blood is drawn for CTC and PSA detection.",
            "SecondaryOutcomeTimeFrame": "12 months after operation"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosed with PCa by biopsy, for the first time.\nClinical assessed suitable for radical prostatectomy\nAge ≥ 18 years, able to provide written informed consent\nNo prior systematic or regional treatment for PCa.\nNo neuro-endocrine differentiation or small cell PCa pattern.\nECOG status 0-1\nExpected life span ≥ 12 months.\nMultiorgan function (heart, lung, liver, kidney) able to tolerate radical prostatectomy, and meet the standard of this study.\n\nExclusion Criteria:\n\nSevere concomitant disease or infection.\nALT or AST > 2.5 ULN, or total bilirubin > 1.5 ULN; Creatinine >177umol/L(2.5mg/dL)；Plt < 100,000/uL, Neutrophil <1,500/uL.\nKnown or suspected brain metastasis or leptomeningeal carcinomatosis.\nAnother malignancy in the last 5 years, excluding completely cured melanoma.\n\nSevere cardiovascular disease, including:\n\nMyocardial infarct within 6 months; Uncontrolled angina pectoris within 3 months; Congestive heart failure; Ventricular arrhythmia history with clinical significance; Morbiz type Ⅱ or complete heart block\n\nMajor surgery (general anesthesia) within 4 weeks.",
      "HealthyVolunteers": "No",
      "Gender": "Male",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      },
      "StudyPopulation": "Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.",
      "SamplingMethod": "Non-Probability Sample"
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Jun Qi, MD.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "021-20578080",
            "CentralContactEMail": "jasonqi@sh163.net"
          },
          {
            "CentralContactName": "Jie Ding, MD.; Postdoc.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+8613564315425",
            "CentralContactEMail": "769233885@qq.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine",
            "LocationStatus": "Recruiting",
            "LocationCity": "Shanghai",
            "LocationState": "Shanghai",
            "LocationZip": "200092",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jun Qi, MD.",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+86-021-25078080",
                  "LocationContactEMail": "qijun@xinhuamed.com.cn"
                },
                {
                  "LocationContactName": "Jun Qi, MD.",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Yes"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011471",
            "ConditionMeshTerm": "Prostatic Neoplasms"
          },
          {
            "ConditionMeshId": "D000000236",
            "ConditionMeshTerm": "Adenoma"
          },
          {
            "ConditionMeshId": "D000009360",
            "ConditionMeshTerm": "Neoplastic Cells, Circulating"
          },
          {
            "ConditionMeshId": "D000011470",
            "ConditionMeshTerm": "Prostatic Hyperplasia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000005834",
            "ConditionAncestorTerm": "Genital Neoplasms, Male"
          },
          {
            "ConditionAncestorId": "D000014565",
            "ConditionAncestorTerm": "Urogenital Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000011469",
            "ConditionAncestorTerm": "Prostatic Diseases"
          },
          {
            "ConditionAncestorId": "D000009375",
            "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
          },
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009362",
            "ConditionAncestorTerm": "Neoplasm Metastasis"
          },
          {
            "ConditionAncestorId": "D000009385",
            "ConditionAncestorTerm": "Neoplastic Processes"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M13487",
            "ConditionBrowseLeafName": "Prostatic Neoplasms",
            "ConditionBrowseLeafAsFound": "Prostatic Neoplasms",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11457",
            "ConditionBrowseLeafName": "Neoplastic Cells, Circulating",
            "ConditionBrowseLeafAsFound": "Circulating Tumor Cells",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M2743",
            "ConditionBrowseLeafName": "Adenoma",
            "ConditionBrowseLeafAsFound": "Adenoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M13486",
            "ConditionBrowseLeafName": "Prostatic Hyperplasia",
            "ConditionBrowseLeafAsFound": "Prostatic Adenoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9168",
            "ConditionBrowseLeafName": "Hyperplasia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8098",
            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16467",
            "ConditionBrowseLeafName": "Urogenital Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13485",
            "ConditionBrowseLeafName": "Prostatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11472",
            "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11482",
            "ConditionBrowseLeafName": "Neoplastic Processes",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}